<DOC>
	<DOCNO>NCT01870375</DOCNO>
	<brief_summary>Neurobehavioral function quality life compromise many patient mucopolysaccharidosis ( MPS ) disorder . The long-term goal research : 1 ) accurately inform patients/parents regard potential neurobehavioral outcome ; 2 ) develop sensitive measure disease progression central nervous system ( CNS ) treatment outcome ; 3 ) help clinical researcher develop direct treatment specific brain structures/functions . The investigator hypothesize specific localize neuroimaging neuropsychological finding relationship distinct MPS disorder . It hypothesize without treatment , function decline structure change time predictable fashion , related locus abnormality stage disease .</brief_summary>
	<brief_title>Longitudinal Studies Brain Structure Function MPS Disorders</brief_title>
	<detailed_description>The mucopolysaccharidoses ( MPS diseases ) lysosomal disorder ( inborn error metabolism ) progressively affect organ system body , usually begin childhood . Recent treatment advance produce amelioration malfunction , notably brain bone difficult effectively treat . This research address brain abnormality MPS disorder , little know . The objective research : 1. identify abnormality central nervous system ( CNS ) structure function well measure quality-of-life ( QOL ) treat untreated MPS patient time . The investigator accomplish longitudinal study enrol patient designated center North America . 2. develop quantitative measurement change , include direct measurement neuropsychological function ; surrogate MRI marker ; biomarkers measure stage disease treatment outcomes . 3. examine degree independent variable impact functional structural outcome . Independent variable may include , limited : age first treatment , severity disease , type medical abnormality , nature genetic mutation , medical event , sensory abnormality . 4. examine treatment Enzyme Replacement Therapy ( ERT ) , Hematopoietic Cell Transplant ( HCT ) , substrate reduction , palliative rehabilitative therapy differentially affect CNS structure function , well subject 's quality life .</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<mesh_term>Osteochondrodysplasias</mesh_term>
	<mesh_term>Mucopolysaccharidosis VII</mesh_term>
	<criteria>Any MPS I , II , IV , VI VII child adult age 625 year Exclusion Criteria Neuroimaging : Participants : Pacemakers Any indwell electronic device include programmable shunt Orthodontic brace unless make metal Other implant metal body titanium Unable stay still MRI low cognitive function , behavioral dysregulation , young age , patient clinical patient sedation/anesthesia Pregnancy Exclusion Criteria Neuropsychological Neurobehavioral Testing Participants : Are functionally impair test</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Mucopolysaccharidosis</keyword>
	<keyword>Longitudinal</keyword>
	<keyword>Brain</keyword>
	<keyword>Cognition</keyword>
	<keyword>Quality-of-Life</keyword>
	<keyword>Hurler syndrome</keyword>
	<keyword>Hunter syndrome</keyword>
	<keyword>Hurler-Scheie syndrome</keyword>
	<keyword>Scheie syndrome</keyword>
	<keyword>Maroteaux-Lamy syndrome</keyword>
	<keyword>MPS I</keyword>
	<keyword>MPS II</keyword>
	<keyword>MPS VI</keyword>
	<keyword>Mucopolysaccharidosis type I</keyword>
	<keyword>Mucopolysaccharidosis type II</keyword>
	<keyword>Mucopolysaccharidosis type VI</keyword>
	<keyword>MPS IV</keyword>
	<keyword>MPS VII</keyword>
	<keyword>Mucopolysaccharidosis type IV</keyword>
	<keyword>Mucopolysaccharidosis type VII</keyword>
	<keyword>Morquio syndrome</keyword>
	<keyword>Sly syndrome</keyword>
</DOC>